D. Craig Allred, M.D. - Funding
Active Research Funding
Principle Investigator; Molecular Classification and Prognostic Profiling of Ductal Carcinoma In Situ (Project 2); Specialized Program of Research Excellence (SPORE) in Breast Cancer; NIH/NCI P50 CA58183; Funding period 12/01/02-11/30/07
Principle Investigator; New Tools and Strategies for Breast Cancer Prevention (Project 2); Research Alliance in Breast Cancer at Baylor College of Medicine; Astra Zeneca; Funding period 7/2003-6/2005
Principle Investigator; Prognostic and Predictive Biomarkers in Ductal Carcinoma In Situ; National Surgical Adjuvant Bowel and Breast Project (NSABP); Funding perior 01/01/01- 12/31/03
Principle Investigator; Development of ER/PR pharmDx IHC Kit; DakoCytomation; Funding period 7/2003-6/2004
Director; Pathology and Tissue Resource; Specialized Program of Research Excellence (SPORE) in Breast Cancer; NIH/NCI P50 CA58183; Funding period 12/01/02-11/30/07
Director; Pathology Core; Chemoprevention of Breast and Ovarian Cancer; NIH/NCI U19 CA86809; Funding period 9/30/99 – 8/31/04
Director; Pathology Core; Mechanisms of Hormonal Prevention of Breast Cancer; NIH/NCI P01 CA64255; Funding period 5/1/02 – 4/30/07
Co-investigator; Mechanism of action of Herceptin in Breast Cancer; NIH/NCI R21 CA87649; Funding period 5/1/00-12/31/03
Co-investigator; Mouse Models of Human Breast Cancer; NIH/NCI U01-CA84243; Funding period 9/30/99 – 3/31/04